A pharmaco-economic study of the administration of adjunctive therapy in patients with chronic epilepsy is described. A decision-analytic model has been used, which represents the consequences of treatment over a 1-year time period, when one of three drugs is used first. The cost-effectiveness ratio for clobazam, lamotrigine and vigabatrin have been calculated.
INTRODUCTION
Ever-increasing demand for healthcare services in an environment of limited resource availability has become a key issue facing the National Health Service. An ageing population, technological advance and rising public expectations with respect to healthcare have all fuelled the demand for funding and brought efficiency in resource use to the top of the health service agenda.
In long-term chronic conditions in particular, clinicians and health service managers alike are increasingly seeking out the most cost-effective form of treatment, thus ensuring maximum outcome from limited budgets.
This paper is concerned with epilepsy and an assessment of the most cost-effective use of alternative adjunctive anticonvulsants. Thus, although it seems clear that the majority of patients can be adequately treated with a single anticonvulsant, in well-tailored monotherapy, for a significant minority additional medications are required. Until recently there were few alternative strategies for use after the more standard anticonvulsants had been tried, alone or in combination. In recent years, several newer drugs have become available, and are at present recommended only for use as polytherapy, being added to an existing anticonvulsant regimen.
Clobazam, a 1,5-benzodiazepine, was one of the first drugs indicated for such use, and the term adjunctive therapy was introduced 1. This has now been followed in the UK by vigabatrin, lamotrigine and gabapentin. The term rational polytherapy is becoming fashionable.
The introduction of these drugs has substantial cost implications for the management of epilepsy. Of these compounds, clobazam is substantially lower priced than the rest, but its use as first line adjunctive therapy has been limited by the development of tolerance in a proportion of patients in whom it initially achieves good control 2. At the same time, a number of patients do retain their initial response to clobazam and are satisfactorily treated over the long-term 3.
The present study considers the economic consequences of prescription of adjunctive anticonvulsant therapies. A decision-analytic model has been developed to represent the consequences of treatment with three drugs as adjuvant therapy in epilepsy over a 1-year time period. The model was used to estimate the expected cost per patient of treatment and the overall proportion of successfully treated patients after 1 year, for each of three treatment alternatives: starting patients on clobazam or vigabatrin or lamotrigine. The 'cost per successfully treated patient', or cost- 
METHODS

Method of treatment consequences
A model of treatment consequences for adjunctive therapy in epilepsy was developed to estimate the expected cost per patient of treatment and the proportion of successfully treated patients for each of the three alternatives (starting patients on either clobazam, vigabatrin or lamotrigine). A treatment period of 1 year was assessed, as this was considered long enough for tolerance to develop in the majority of patients if it was going to do so 1 and for the long-term effects of therapy to be examined. The model was developed based on clinical experience with the drugs and a review of relevant literature, and is best explained with reference to Fig. 1 .
Seizure 'control' at any point was defined as having at least a 50% reduction in seizure frequency relative to pre-treatment levels. For patients receiving clobazam, initial control could be lost at 3, 6, 9 or 12 months, depending on whether or not tolerance developed. By contrast, for patients treated with vigabatrin or lamotrigine, it was assumed that initial control at 3 months was retained over the longterm, with no drop-out due to tolerance (the implications of this are discussed later).
At any point where a patient was not controlled, treatment was switched to another therapy, as would be the case in normal clinical practice. Patients initially on clobazam were switched to vigabatrin in the event of failure, and subsequently to lamotrigine if a second failure occurred. For patients treated initially with vigabatrin, lamotrigine was given if treatment failed, followed by cloba-zam, and for those treated initially with lamotrigine, vigabatrin was given, then clobazam. When a third failure occurred, a fourth new adjunctive therapy, gabapentin, was administered.
A patient was defined as a treatment success if they met two specific criteria: These two criteria, associated with routes 1, 3, 5 and 8 in the model, reflected as fully as possible the definition of 'successful treatment' considered most relevant to the 'real world' situation. By estimating the proportion of patients following these four routes for each of the three drugs, an overall percentage of successfully treated patients could be obtained in each case.
Long
The expected cost per patient of treatment for each drug was calculated by summing the estimated costs of all twelve routes through the model, weighted by the proportion of patients expected to follow them.
Cost data
Cost data incorporated into the model included the cost of any drug treatment given, both initially and if treatment was switched, and the cost of extra clinic visits, should a patient not be controlled on their current therapy. It was assumed that the costs of treating sideeffects and of any necessary blood monitoring activity were equivalent for each of the three drugs and did not therefore need to be included in the analysis. The implications of this assumption are addressed later. 39 Recommended drug dosage regimens and unit drug costs for clobazam, vigabatrin, lamotrigine and gabapentin were obtained from the Monthly Index of Medical Specialities (MIMS), October 1993 a. Dosage regimens used in clinical practice, where these differed from the doses recommended in MIMS, were obtained from personal preference, and discussion with colleagues.
The unit cost of a clinic visit was estimated from the cost of an outpatient attendance published by the Department of Health in 19904 , inflated to 1993 prices ~'s. The expected number of extra clinic visits incurred when a patient was not controlled was calculatd from our own clinical experience.
Clinical data
Clinical data incorporated into the model included efficacy rates for clobazam at 3, 6, 9 and 12 months, and for vigabatrin and lamotrigine at 3 months only (it has been assumed there was no long-term drop-out with the newer drugs}. Efficacy rates were required in terms of the proportion of patients achieving at least a 50% reduction in seizures relative to baseline.
Data for vigabatrin were obtained from a review published in 19937, which included a summary of all short-term trials completed on the drug up to that time. An average and maximum/minimum values were obtained from the three 3-month trials within the review, and the average used as the 'basecase' efficacy value for vigabatrin.
Rates for lamotrigine were obtained from a review published in 1991 s, which included a summary of four single-centre controlled trials, one multi-centre controlled trial and 27 open studies involving lamotrigine, all of which had a treatment period of approximately 3 months. Again, an average and maximum/ minimum values were calculated from these three sources of data, with the average used as the basecase efficacy value.
Efficacy rates for clobazam were obtained from the only two trials apparent in the literature a, lo which provided data on the proportion of patients with a 50% reduction in seizures at 3, 6, 9 and 12 months. In selecting these trials, all studies in the 1986 review of clobazam by Robertson I were considered, as were later publications by Heller, Buchanan and Guberman 11-1a. Only the studies by Allen in Three month efficacy rates for the fourth drug, gabapentin, were also required for the model. A summary figure for the proportion of patients achieving a 50% or more reduction in seizures on gabapentin was obtained from a short review of new adjunctive anticonvulsants published in 1993.14
Cost-effectiveness ratios
The expected cost per patient of treatment and the overall proportion of successfully treated patients after 1 year's therapy for each of the three alternatives were obtained from the completed model and used to calculate a costeffectiveness ratio (CER) in each case, using the formula below; CER = Cost per successfully treated patient = Expected cost per patient of treatment % of successfully treated patients
The treatment alternative with the lowest cost-effectiveness ratio effectively represents optimal value for money.
A number of sensitivity analyses were carried out to test the robustness of the model. Variables tested included efficacy rates for all three drugs, their dosage regimens (and thus drug costs}, and the number of extra clinic visits incurred if a patient was not controlled on their current treatment.
RESULTS
Cost data
The range of dosage regimens and associated drug costs obtained in the analysis is outlined in Table 1 . Based on the doses recommended in MIMS (i.e. the basecase situation}, drug costs for vigabatrin and lamotrigine were approximately seven to eight times higher than those for clobazam, with lamotrigine slightly more expensive than vigabatrin. The costs of lamotrigine were greatly reduced if it was to be used in conjunction with valproate, thus requiring the dose to be halved. It was still, however, more than four times as expensive as clobazam and, in clinical practice, would also require regular blood monitoring to be conducted when used with valproate, thus raising the cost once again.
The dosage regimens used in clinical practice differ from those recommended in MIMS for clobazam and vigabatrin, and were more conservative in both cases, thus lowering the basic drug cost. In addition, the cost of the fourth medicine, gabapentin, was calculated at £165.10 for 3 months treatment :~, the maximum time for which it was administered in the model.
The unit cost of an extra clinic visit, required if seizures were not controlled, was calculated at £40.004-6. It was considered that, in normal circumstances, no extra clinic visits would be incurred as a result of poor control of a patient's epilepsy, since the majority of patients would be already attending clinics on a regular basis, probably at least as often as once every 3 months and particularly after starting a new drug. Therefore, in the basecase situation, no additional clinic visits were included in the analysis. However, one extra clinic visit per 3-month period in which a patient was not controlled, was incorporated into the sensitivity analysis.
Clinical data
The efficacy rates for clobazam, vigabatrin and lamotrigine used in the analysis are outlined in Table 2 . In each case, basecase, maximum and minimum values are given for the percentage of patients controlled on each drug at the relevant time periods. Initial 3-month efficacy rates were highest with vigabatrin (45% of patients with at least a 50% reduction in seizures) and lowest with lamotrigine (26% of patients meeting the same criteria). However, the longer-term drop-out with clobazam over time resulted in a final basecase efficacy rate for clobazam of 21% at 12 months.
The basic 3-month efficacy rate for gabapentin was 42c/c ~4.
Cost-effectiveness ratios
By inputting the cost and clinical data into the model, the expected cost per patient of treatment and the overall proportion of successfully treated patients were obtained for each of the three comparators and used to calculate the cost per successfully treated patient, or costeffectiveness ratio, in each case {Table 3).
The expected cost per patient of treatment over the 1-year period was up to 50% higher when patients were started on vigabatrin {£858) or lamotrigine (£877) rather than on clobazam (£584). However, only 2.7% more patients would be successfully treated at the end of the 12 months when started with the newer drugs. As a result, the cost per successfully treated patient, or cost-effectiveness ratio, for the vigabatrin and lamotrigine options was around 40% higher than for clobazam.
The strength of this result was tested using several sensitivity analyses, the findings of which are presented in Table 4 . When a number of key variables were changed in the model in order to favour vigabatrin and lamotrigine (conditions 1-5, Table 4 ), the cost- effectiveness advantage for clobazam, though reduced to varying degrees, was still retained. A 'worst case' scenario was then tested Icondition 6, Table 4 ) in which all of the conditions 1-5 were imposed simultaneously twith the exception of number 3 which had no impact on relative cost-effectiveness*). In this case, the result altered to favour the newer drugs, although the magnitude of the cost-effectiveness advantage was small {around 10ok}.
When the opposing situation was tested, with all variables changed to favour clobazam (condition 7, Table 4 ), the 1,5-benzodiazepine became almost twice as cost-effective as vigabatrin or lamotrigine.
DISCUSSION
A number of points should be highlighted before suggesting that the study findings may be used as a basis for decision-making.
First, we have not assessed the direct costeffectiveness of clobazam, vigabatrin and lamotrigine. The present study considers the cost-effectiveness of starting patients on each treatment, with subsequent changes in therapy if necessary. Thus the complete treatment package is taken into consideration, not just the effects of initial therapy. So, for example, a patient not controlled after 3 months on clobazam who subsequently achieves long-term control with vigabatrin is classified as a treatment success for the clobazam group. Equally, a patient initially uncontrolled on vigabatrin but later successful on lamotrigine, can be defined as a success for the vigabatrin alternative. This approach is adopted as the most relevant to the 'real world' situation, but must nonetheless be borne in mind in interpreting the study findings. We accept the fact that our comparisons are based on the outcomes of published clinical trials, which may not ultimately reflect clinical practice. However, the data are in the public domain, and must represent the best available source of our information about the new drugs. We are currently applying the model described above to clinical practice. However, in the meantime the figures we have arrived at are based on pharmaco-economic principles, of the sort that are more and more being employed in evaluating health care and its delivery.
The chosen definition of treatment success is also significant, as changes in this definition are likely to affect the results. For example, if the level of control required in the study was changed from a 50% reduction in seizure frequency to the complete eradication of seizures, then the result would be different, probably acting in this case to further support clobazam and vigabatrin since a relatively high proportion of patients are seizure-free when treated with these agents 1'7' s. is. By contrast, if only patients controlled for 12 months during the initial treatment period were to be defined as treatment successes (i.e. not permitting 3 months without control early on in the course of achieving long-term success), then the results would more likely favour vigabatrin and lamotrigine.
In addition, two assumptions have been made which may have also influenced the study outcome. First, it was assumed that, once controlled on either vigabatrin or lamotrigine, patients retained that control for the remainder of the treatment period, with no long-term drop-out due to tolerance. This assumption may have favoured vigabatrin and lamotrigine in the analysis by overestimating their longterm effectiveness (in practice, there is some evidence of withdrawal from these drugs, certainly in the case of vigabatrinT). As a result, it is possible that the cost-effectiveness advantage demonstrated for clobazam in the study has been under-represented.
The second assumption, which may have also under-estimated the cost-effectiveness of clobazam, was the omission of the costs of blood monitoring and treating side-effects from the model, on th~ ~rounds that they were approximately equivalent for all three drugs. Again, there is evidence to suggest that these two sources of cost are in fact higher for vigabatrin and lamotrigine: blood monitoring is more likely to be required with the newer drugs due to the greater risk of drug interactions 1"2'v'~6 while side-effects can be more severe and thus most costly in a small proportion of patients on vigabatrin and lamotrigine (due to behaviour change and rash, respectively) 2' v. is, 16 .
Within these constraints, however, conclusions can still be drawn from the analysis. There appears to be a clear cost-effectiveness advantage demonstrated for clobazam over vigabatrin and lamotrigine. In clinical terms, when adjunctive therapy is required, this is the most cost effective drug of the three to begin treatment with. What this means in practice is that it costs substantially less to achieve successful treatment after 1 year when patients are started on clobazam rather than on vigabatrin or lamotrigine.
In a situation of limited budgets, more patients are successfully treated using clobazam as the first choice adjunctive drug rather than vigabatrin or lamotrigine. For example, if an epilepsy clinic had an annual budget of £50 000 for adjunctive therapy, then, based on the results in Table 3 , around 48 patients can be successfully treated using clobazam first (£1034 per successfully treated patient) compared with only 33 or 34 patients iflamotrigine or vigabatrin are the first choice drugs (£1479 and £1447 per success, respectively).
Even when budgets are not fixed, the study results still strongly favour the use of clobazam. If, for example, 50 patients are treated at an epilepsy clinic over the course of 1 year, then the total expected cost of treatment is around £29000 when clobazam is used first (derived from Table 3 ), compared with £43-44000 for the vigabatrin or lamotrigine alternatives. Despite this extra £14-15 000 of expenditure, however, only one additional patient is successfully treated using the newer drugs (29 successfully treated patients for vigabatrin or lamotrigine vs 28 for clobazam). Additional analysis is recommended either to develop the present study further (e.g. incorporating side-effects and blood monitoring costs into the analysis) or to address other costeffectiveness issues in the field of epilepsy, such as the value for money of surgical intervention or vocational rehabilitation programmes. Quality of life determination should also be incorporated into such models. Either way, the need to examine the most efficiant use of resources is long-term chronic conditions such as epilepsy is likely to become increasingly significant in future years.
